Author

Dino Tarabar 1

1 Military Medical Academy, Belgrade, Serbia

CLINICAL OUTCOMES IN CONTINUOUS CLINICAL RESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUB-ANALYSES FROM THE PURSUIT-SC MAINTENANCE STUDY

W Reinisch, Brian G. Feagan, C Marano, R Strauss, Jewel Johanns, H Zhang, H Weng, R Yao, Dino Tarabar, Zbigniew Hebzda

FECAL LACTOFERRIN AND CALPROTECTIN AS SURROGATE MARKERS OF MUCOSAL HEALING: POST-HOC ANALYSIS FROM THE PURSUIT SC INDUCTION STUDY

Walter Reinisch, William Sandborn, Brian G. Feagan, Paul Rutgeerts, Peter R. Gibson, Judy Collins, Dino Tarabar, Zbigniew Hebzda, Jean-Frederic Colombel, Colleen W. Marano, Richard S Strauss, Jewel Johanns, Hongyan Zhang

HOW LONG SHOULD GOLIMUMAB TREATMENT BE CONTINUED IN PATIENTS WITH ULCERATIVE COLITIS WHO DO NOT RESPOND TO INITIAL INDUCTION THERAPY?

Paul Rutgeerts, Walter Reinisch, Brian G. Feagan, William Sandborn, Dino Tarabar, Zbigniew Hebzda, Ruji Yao, Colleen W. Marano, Richard S Strauss

LONG TERM FOLLOW-UP OF PATIENTS WITH SEVERE, STEROID-RESISTANT ULCERATIVE COLITIS WHO RECEIVED INDUCTION THERAPY WITH CYCLOSPORINE AND WERE MAINTAINED WITH VEDOLIZUMAB

Dino Tarabar

LONG TERM FOLLOW-UP OF PATIENTS WITH SEVERE, STEROID-RESISTANT ULCERATIVE COLITIS WHO RECEIVED INDUCTION THERAPY WITH CYCLOSPORINE AND WERE MAINTAINED WITH VEDOLIZUMAB

Dino Tarabar, Katia El Jurdi, Olivia Yvellez, Zoran Milenkovic, Stanko Petrovic, Bojana Subotic, Tanja P Brocic, Irina Brcerevic, Olgica Latinovic, Tatiana Jocic, David T. Rubin

Long-term mucosal healing, clinical response and clinical remission in patients with ulcerative colitis treated with the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody ontamalimab (SHP647): results from the open-label extension study TURANDOT II

Silvio Danese, William Sandborn, Walter Reinisch, Xavier Hebuterne, Maria Kłopocka, Dino Tarabar, Tomáš Vaňásek, Miloš Greguš, Paul A Hellstern, Joo Sung Kim, Miles P. Sparrow, Kenneth Gorelick, Martina Goetsch, Caleb Bliss, Charu Gupta, Fabio Cataldi, Severine Vermeire

LONG-TERM SAFETY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II)

Walter Reinisch, William Sandborn, Silvio Danese, Xavier Hebuterne, Bruce Salzberg, Maria Kłopocka, Dino Tarabar, Tomáš Vaňásek, Miloš Greguš, Paul A Hellstern, Joo Sung Kim, Miles P. Sparrow, Kenneth Gorelick, Martina Goetsch, Caleb Bliss, Fabio Cataldi, Severine Vermeire

LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MADCAM-1 MONOCLONCAL ANTIBODY SHP647 IN CROHN'S DISEASE: THE OPERA II STUDY

Geert R. D'Haens, Walter Reinisch, Scott D. Lee, Dino Tarabar, Edouard Louis, Maria Kłopocka, Jochen G. Klaus, Stefan Schreiber, Dong Il Park, Xavier Hebuterne, Fabio Cataldi, Steven W Martin, Satyaprakash Nayak, Anindita Banerjee, Kenneth Gorelick, William Sandborn

TOFACITINIB FOR INDUCTION THERAPY IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS IN TWO PHASE 3 CLINICAL TRIALS: RESULTS BY LOCAL AND CENTRAL ENDOSCOPIC ASSESSMENTS

Brian G. Feagan, Severine Vermeire, Walter Reinisch, William Sandborn, Dino Tarabar, Wojciech Niezychowski, Chinyu Su, Haiying Zhang, Deborah A. Woodworth, Dahong Yu, Bruce E. Sands

TOFACITINIB FOR MAINTENANCE THERAPY IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS IN THE PHASE 3 OCTAVE SUSTAIN TRIAL: RESULTS BY LOCAL AND CENTRAL ENDOSCOPIC ASSESSMENTS

Brian G. Feagan, Severine Vermeire, William Sandborn, Walter Reinisch, Julian Panés, Dino Tarabar, Chinyu Su, Wojciech Niezychowski, Haiying Zhang, Gary S. Friedman, Deborah A. Woodworth, Bruce E. Sands

Item 1 - 10 / 11
1
2